Compare Air Products & Chemicals, Inc. (APD) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs Cytokinetics Inc — how do they compare? Air Products & Chemicals, Inc. trades at $296.7 (market cap $66.70B), while Cytokinetics Inc trades at $83.2 (market cap $11.52B). The key difference: Air Products & Chemicals, Inc. is far larger — about 5.8× Cytokinetics Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.42% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| APD | CYTK | |
|---|---|---|
Market Cap | $66.70B | $11.52B |
Sector | Basic Materials | Technology |
52-Week High | $314.19 | $87.26 |
52-Week Low | $230.42 | $33.23 |
Enterprise Value | $84.11B | $11.99B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APD trades at $299.53, up 1.24% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and strategic project exits, like the Louisiana Clean Energy Complex, have boosted investor confidence. The company maintains solid profitability margins but faces pressure from a negative net income in 2025 due to a pre-tax charge. Cash flow trends show volatility, with significant investing outflows for growth initiatives.
The outlook is positive with a consensus price target of $324.89, implying ~8% upside. Risks include high debt levels, execution on new projects, and macroeconomic sensitivity. Long-term growth is supported by renewable energy investments, but near-term profitability recovery is key for sustained gains.
Cytokinetics (CYTK) trades at $84.87, down 1.39% today, with a bullish technical signal from moving averages and strong analyst support. The company's recent FDA approval of Myqorzo and European launch drive optimism, though financials show significant losses with a net income margin of -784.02% and negative cash flow from operations of -$510.01 million in 2025. Revenue growth is projected from $88 million to $106 million in 2026, but profitability remains a challenge.
The outlook hinges on Myqorzo's commercial success, with a consensus price target of $110.40 implying 30% upside. Risks include high cash burn, competitive pressures, and reliance on drug adoption. Institutional sentiment is overwhelmingly bullish, but investors must weigh the growth potential against persistent financial losses and execution risks in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
